Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy.
Mike WenzelCristina Cano GarciaBenedikt HoehCharlotte JoriasClara HumkeFlorestan KollNikolaos TselisClaus RödelMarkus GraefenDerya TilkiFelix K H ChunPhilipp MandelPublished in: The Prostate (2023)
Our real-world data suggest that MDT represents a safe treatment option for well-selected oligometastatic mHSPC patients.
Keyphrases
- prostate cancer
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- radical prostatectomy
- electronic health record
- type diabetes
- adipose tissue
- patient reported outcomes
- mesenchymal stem cells
- skeletal muscle
- insulin resistance
- cell therapy
- data analysis